* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2PQ vs SIGA, ELTP, TKNO: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (STU:2PQ) has a OCF Margin % of 58.28% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #563 out of 959 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is Organogenesis Holdings' OCF Margin % too high?
Organogenesis Holdings' current OCF Margin % is 58.28%. The Drug Manufacturers industry median OCF Margin % is 9.94. Organogenesis Holdings' value of 58.28% is 486.3% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #563 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' OCF Margin % compare to SIGA and ELTP?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #563 out of 959 companies for OCF Margin %. This places Organogenesis Holdings in the lower half of its industry. The industry median OCF Margin % is 9.94. Organogenesis Holdings' value of 58.28% is 486.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current OCF Margin % of 58.28% is 486.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current OCF Margin % is 58.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.12 — trading 23.2% below its estimated fair value. The current OCF Margin % is 58.28% and 486.3% above the Drug Manufacturers industry median of 9.94. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current OCF Margin % is 58.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.12 is trading 23.2% below its estimated GF Value™ of €2.76.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for STU:2PQ:
OCF Margin %: 58.28%
GF Value™: €2.76 vs. price of €2.12 (23.2% below fair value)
Industry Position: 486.3% above the Drug Manufacturers median (#563 of 959)
No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for STU:2PQ
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2PQ has been successfully added to your 
